Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Self-report of smoking an average of ≥10 cigarettes/day for 6 months and expired carbon monoxide (CO) ≥10 parts per million (ppm) or urine cotinine ≥ 100 ng/mL at screening or self-report of smoking an average of 5-9 cigarettes/day for 6 months and a urine cotinine ≥30ng/ml at screening~* Have a negative urine drug screen at screening~* Fertile, sexually active subjects (males and females) must use an effective method of contraception from the first dose of study drug and for 3 months after the last dose of study drug~* If female and capable of conception, must have a negative urine Human chorionic gonadotrophin (hCG) pregnancy test at screening and Day 1~Exclusion Criteria:~* Have unstable medical illness with hospitalization for treatment likely within 6 months~* Have life-threatening arrhythmia, cerebrovascular or cardiovascular event within 6 months of enrollment~* Have liver function tests elevated \>2.5 times the upper limit of normal range~* Have a tumor or a seizure disorder~* Currently using other tobacco- or nicotine-containing products and unwilling to try to quit~* Have a 6-month history of substance use disorder other than nicotine or caffeine or major depressive disorder~* Have a history of multiple adverse drug reactions~* Non-response (past 3 months) to nicotine replacement therapy (NRT) \>20 mg/day, bupropion \>150 mg/day, or varenicline 2 mg/day for ≥4 weeks~* Use of excluded concomitant medications~* Hospitalization for any reason within 30 days of screening~* Use of any investigational drug or device within 30 days of screening~* Have clinically significant abnormal serum electrolytes~* Have insufficiently controlled diabetes mellitus~* Have renal insufficiency (serum creatinine \>1.8 mg/dL)~* Malignant tumor within the last 5 years, with the exception of squamous and basal cell carcinoma or cervical carcinoma in situ~* Have a clinically significant cardiovascular abnormality on the screening EKG~* Lifetime history of schizophrenia, bipolar disorder, post-traumatic stress disorder, bulimia, organic mental disorder, dementia, pervasive developmental disorder~* Have untreated, clinically significant hypothyroidism or hyperthyroidism~* Have a positive self-report of human immunodeficiency virus infection~* Females who are pregnant or nursing~* Any experimental drug currently or within 30 days before baseline~* Have a serious risk of suicide~* Have a screening electrocardiogram (ECG) with a corrected QT (QTc) interval using Bazett's formula \>450 msec for males and \>470 msec for females or the presence of any clinically significant cardiac abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- EVP-6124 + NicoDerm (Active) (Type: EXPERIMENTAL): One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
- Placebo + NicoDerm (Active) (Type: ACTIVE_COMPARATOR): One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
- EVP-6124 + NRT Patch (Placebo) (Type: EXPERIMENTAL): One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
- Placebo + NRT Patch (Placebo) (Type: PLACEBO_COMPARATOR): One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval